Comparative Analysis of Biopharmaceutical Companies: Krystal Biotech, and Mersana Therapeutics
Font: Financial Modeling Prep • Oct 11, 2025
- Krystal Biotech, Inc. shows the highest growth potential among its peers, with a positive target price difference of 38.70%.
- Mersana Therapeutics, Inc. has a negative target price difference, indicating a less favorable outlook compared to Krystal Biotech.
Krystal Biotech, Inc. is a clinical-stage biotechnology company that specializes in gene therapy for rare diseases. It shows the highest growth potential among its peers, with a target price difference of 38.70%. Currently, KRYS is priced at $181.47, with a target price of $251.70, indicating a more optimistic outlook from analysts.
Mersana Therapeutics, Inc. is another peer in the biotechnology sector, focusing on developing antibody-drug conjugates for cancer treatment. However, MRSN has a negative target price difference, suggesting a less favorable outlook compared to Krystal Biotech. Its stock is priced at $9.24, reflecting the challenges it faces in the market.
Overall, Krystal Biotech stands out among its peers with the most optimistic growth potential. Its focus on gene therapy for rare diseases and the significant target price difference highlight its promising position in the biotechnology sector.
Market Overview
|
LBGJ
Li Bang International Corporation Inc. Ordinary Shares
|
$0.03
5.00%
|
|
MOBX
Mobix Labs, Inc.
|
$0.58
25.22%
|
|
TZA
Direxion Daily Small Cap Bear 3X ETF
|
$7.23
-1.90%
|
|
BITO
ProShares - Bitcoin ETF
|
$9.67
-1.12%
|
|
NVDA
NVIDIA Corporation
|
$178.56
-1.02%
|
|
SER
Serina Therapeutics, Inc.
|
$2.51
96.11%
|
|
TQQQ
ProShares - UltraPro QQQ
|
$45.69
-0.89%
|
|
SPDN
Direxion Daily S&P 500 Bear 1X ETF
|
$9.87
0.20%
|
|
DVLT
Datavault AI Inc.
|
$0.80
-14.29%
|
|
SPY
State Street SPDR S&P 500 ETF Trust
|
$659.81
-0.24%
|
